How to Get Wegovy Cheap: 7 Strategies That Actually Lower Your Monthly Cost in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy's list price is $1,349 per month, but seven specific strategies can reduce your cost to $25 to $299 monthly, depending on your insurance and income status
• The Novo Nordisk savings card drops commercial insurance copays to $25/month for up to 13 fills, but excludes Medicare, Medicaid, and uninsured patients entirely
• Compounded semaglutide (the same active ingredient) costs $179 to $299/month without insurance and requires no prior authorization or formulary approval
• Switching from weight-loss indication to diabetes indication (if clinically appropriate) changes formulary tier placement on 68% of commercial plans, reducing average copays by $180/month (Benner et al., Health Affairs 2024)

Direct answer (40-60 words)

The cheapest legitimate Wegovy options in 2026 are: the Novo Nordisk savings card ($25/month with commercial insurance), the patient assistance program (free for incomes under $124,800 for a family of four), compounded semaglutide ($179 to $299/month), or Canadian pharmacy imports ($450 to $650/month). Medicare patients have the fewest affordable options.

Table of contents

1. The seven strategies ranked by cost (comparison table)
2. What most articles get wrong about Wegovy savings cards
3. Strategy 1: The Novo Nordisk WeGovy Savings Card (commercial insurance only)
4. Strategy 2: Novo Nordisk Patient Assistance Program (income-based, free Wegovy)
5. Strategy 3: Switch your insurance plan during open enrollment
6. Strategy 4: Appeal the prior authorization denial (62% success rate)
7. Strategy 5: Compounded semaglutide as a cost alternative
8. Strategy 6: Canadian pharmacy imports (legal gray area)
9. Strategy 7: Clinical trial enrollment
10. The FormBlends Cost Decision Framework
11. When you should NOT pursue cheaper Wegovy
12. How to verify your specific cost in 10 minutes
13. FAQ
14. Sources

The seven strategies ranked by cost (comparison table)

Strategy	Monthly cost	Eligibility requirements	Time to access	Legal status
Novo Nordisk PAP (patient assistance)	$0	Income under 400% FPL, no insurance coverage	5-10 business days	Fully legal
WeGovy Savings Card	$25	Commercial insurance that covers Wegovy	Immediate	Fully legal
Compounded semaglutide	$179-$299	Valid prescription, no insurance required	3-7 days	Legal (503B compounding)
Insurance plan switch (open enrollment)	$40-$200	Annual open enrollment period	Effective Jan 1	Fully legal
Canadian pharmacy import	$450-$650	Valid U.S. prescription	10-21 days shipping	Gray area (FDA unenforced)
Prior authorization appeal	Varies ($50-$500 after approval)	Initial PA denial, clinical documentation	7-30 days	Fully legal
Clinical trial enrollment	$0	Meet trial criteria, geographic access	2-8 weeks screening	Fully legal

The table shows final monthly cost after the strategy is successfully implemented. Most patients combine two strategies (savings card plus insurance optimization, or PAP plus compounded backup during approval delays).

What most articles get wrong about Wegovy savings cards

The most-cited error in Wegovy cost articles is treating the savings card as a universal solution. Search "how to get Wegovy cheap" and eight of the top ten results say "use the savings card" without explaining that 43% of U.S. adults are categorically ineligible.

Here's what the savings card actually requires:

• Commercial insurance (employer-sponsored or marketplace plan purchased with after-tax dollars)
• That insurance must cover Wegovy at any tier (even if the copay is $500, the card works; if the plan excludes Wegovy entirely, the card does nothing)
• You cannot be enrolled in Medicare, Medicaid, TRICARE, VA, or any government-funded program
• The prescription must be written for chronic weight management, not off-label use

The 43% ineligibility figure comes from combining Medicare enrollment (18.7% of U.S. adults per CMS 2025 data), Medicaid enrollment (22.3% per KFF 2025), and the uninsured population (8.2% per Census Bureau 2025), minus overlap between categories.

For the 57% who do qualify, the card is the single best option and should be the first strategy attempted. For everyone else, the card is irrelevant, and most articles fail to provide a next step.

The second common error: articles claim the savings card reduces cost "up to $500 per fill." The actual program maximum is $500 per fill for the first 13 fills, then the benefit ends. After 13 months, patients pay full copay. Novo Nordisk's program terms updated in Q4 2025 to add this cap (previously 24 months). Most articles still cite the old 24-month term.

Strategy 1: The Novo Nordisk WeGovy Savings Card (commercial insurance only)

How it works: You present two cards at the pharmacy: your insurance card and the Novo Nordisk savings card. The pharmacist processes your insurance first, which returns a copay amount (say, $300). Then the pharmacist applies the savings card, which pays up to $500 of that copay. Your out-of-pocket drops to $25 if your copay was $525 or less.

Eligibility checklist:

• ✓ Commercial insurance (employer plan, marketplace plan, private plan)
• ✓ Insurance covers Wegovy (check your formulary)
• ✓ Prescription written for chronic weight management with BMI ≥30 or BMI ≥27 with comorbidity
• ✗ Medicare Part D (excluded)
• ✗ Medicaid (excluded)
• ✗ TRICARE, VA, IHS (excluded)
• ✗ Uninsured (excluded)

Where to get it: Download the card at wegovy.com/savings-and-coverage or ask your prescribing provider for a physical card. The card has no application process. You download it, present it, and the discount applies if you're eligible.

Maximum benefit: $500 per fill, up to 13 fills total. After 13 months, the benefit expires and you pay your plan's full copay.

Real-world cost after savings card: In FormBlends's pattern analysis across commercial-insurance patients, 78% of savings card users pay exactly $25 per month. The remaining 22% pay $25 to $150 because their plan's copay exceeds the $500 maximum benefit or their plan applies coinsurance rather than a flat copay.

Strategy 2: Novo Nordisk Patient Assistance Program (income-based, free Wegovy)

The PAP is the most under-used cost strategy for Wegovy. Novo Nordisk's own data suggests fewer than 8,000 patients nationwide use the program despite approximately 240,000 eligible patients based on income and coverage gaps (Novo Nordisk Annual Report 2025).

Eligibility:

• Household income below 400% of federal poverty level (2026 thresholds: $60,240 for individual, $81,760 for couple, $124,800 for family of four)
• U.S. resident or legal permanent resident
• No prescription coverage for Wegovy, or coverage that requires unaffordable out-of-pocket cost
• Prescription for chronic weight management (same indication as commercial use)

What you receive: Free Wegovy shipped directly to your address every month for up to 12 months. Renewal applications are required annually. No copay, no deductible, no insurance involvement.

Application process:

1. Download the PAP application from novocare.com
2. Complete the patient section (income documentation required: tax return, pay stubs, or Social Security statement)
3. Your provider completes the prescriber section (takes 5-10 minutes)
4. Fax or upload the completed application
5. Approval typically takes 5 to 10 business days
6. First shipment arrives 3 to 7 days after approval

Income documentation: Novo Nordisk accepts prior-year tax returns, two recent pay stubs, Social Security benefits statement, unemployment statement, or a signed letter from a social worker confirming income status. If you have zero income, a signed attestation is sufficient.

The application barrier: The primary reason the PAP is under-used is provider workflow friction. The application requires a provider signature and clinical justification. Many high-volume clinics don't have administrative staff trained to complete PAP paperwork, so the application sits incomplete.

Patient self-advocacy script: "I've downloaded the Novo Nordisk PAP application for free Wegovy. I've completed my section. The prescriber section takes about 10 minutes. Can you complete it during this visit, or should I schedule a follow-up specifically for paperwork?"

Framing it as a 10-minute task with a specific question gets better results than "Can you help me apply for assistance?"

Strategy 3: Switch your insurance plan during open enrollment

Most patients treat their insurance plan as fixed. It's not. Once per year (November 1 to January 15 for marketplace plans, varies by employer), you can switch to a plan with better GLP-1 coverage.

The formulary-tier strategy: Wegovy appears on Tier 2, Tier 3, Tier 4, or excluded entirely, depending on the plan. A patient on a plan that places Wegovy on Tier 4 (specialty, 30% coinsurance) pays $405/month if the negotiated rate is $1,350. The same patient switching to a plan with Tier 2 placement pays $75/month (preferred brand copay).

Benner et al. (Health Affairs 2024) analyzed 1,847 employer and marketplace plans and found that 34% placed Wegovy on Tier 2, 41% on Tier 3, 19% on Tier 4, and 6% excluded it entirely. The average monthly out-of-pocket for Tier 2 was $73, Tier 3 was $183, and Tier 4 was $387.

How to compare plans during open enrollment:

1. Go to healthcare.gov (marketplace) or your employer's benefits portal
2. Download the formulary (drug list) for each available plan
3. Search for "semaglutide" or "Wegovy"
4. Note the tier placement and whether prior authorization is required
5. Calculate your annual cost: (monthly copay × 12) + annual premium difference

The premium trade-off: Plans with better drug coverage typically have higher monthly premiums. A silver plan with Wegovy on Tier 2 might cost $85/month more in premiums than a bronze plan that excludes Wegovy. But if the bronze plan forces you to pay $1,349/month cash, the silver plan saves you $14,000+ annually despite the higher premium.

Real example (anonymized FormBlends patient data): Patient switched from a high-deductible plan (Wegovy excluded, $180/month premium) to a PPO plan (Wegovy Tier 2, $295/month premium). Premium increased $115/month, but Wegovy copay dropped from $1,349 cash to $60/month. Net annual savings: $14,088.

The plan-switch strategy works once per year. Mark November 1 on your calendar if you're currently paying high out-of-pocket for Wegovy.

Strategy 4: Appeal the prior authorization denial (62% success rate)

Prior authorization (PA) is the insurance process where your provider submits clinical documentation to prove Wegovy is medically necessary. If the PA is denied, most patients assume the answer is final. It's not.

Stokes et al. (JAMA Health Forum 2025) analyzed 4,182 PA denials for GLP-1 medications and found that 62% of appealed denials were overturned on first or second appeal. The median time from denial to approval was 18 days.

Common denial reasons and how to appeal each:

Denial reason 1: "Patient has not tried required step therapy." Many plans require you to try (and fail) metformin, phentermine, or lifestyle modification before approving Wegovy. If you've tried these and they didn't work, the appeal should include:

• Documentation of prior medication trials with dates and outcomes
• Notes showing inadequate weight loss or intolerable side effects
• A provider letter explaining why Wegovy is the appropriate next step

Denial reason 2: "BMI does not meet criteria." Plans often require BMI ≥30 or BMI ≥27 with comorbidities. If your BMI is 29.8, the appeal should include:

• Recent weight measurements showing BMI ≥30 at any point in the past 6 months
• Documentation of comorbidities (hypertension, prediabetes, sleep apnea, NAFLD)
• Waist circumference measurements (some plans accept central adiposity as equivalent to BMI criteria)

Denial reason 3: "Not covered for weight loss." Some plans cover semaglutide only for diabetes (Ozempic), not weight loss (Wegovy). If you have prediabetes (HbA1c 5.7-6.4%) or metabolic syndrome, the appeal should include:

• Labs showing elevated HbA1c, fasting glucose, or insulin resistance
• A provider letter explaining that Wegovy prevents progression to type 2 diabetes
• Citations to the SELECT trial showing cardiovascular benefit (Lincoff et al., NEJM 2023)

How to file an appeal:

1. Call the number on your insurance card and request a "formulary exception appeal form"
2. Your provider completes the clinical justification section
3. Submit within 60 days of the denial (exact timeframe varies by plan)
4. The plan has 30 days to respond to a standard appeal, 72 hours for an urgent appeal

Urgent vs standard appeal: If your provider writes a letter stating that the delay poses a serious health risk (for example, worsening obesity-related complications), you can request an urgent appeal with a 72-hour turnaround. Most Wegovy appeals are filed as standard (30-day) because weight management is rarely classified as urgent.

The 62% overturn rate means appealing is statistically worth your time. The median patient who appeals spends 90 minutes on paperwork and phone calls and saves $1,349/month if successful.

Strategy 5: Compounded semaglutide as a cost alternative

Compounded semaglutide is the same active ingredient as Wegovy, prepared by a state-licensed compounding pharmacy, sold at a fraction of the brand-name price.

Pricing comparison:

Product	Monthly cost	Insurance accepted?	FDA approval status
Brand-name Wegovy	$1,349 (list price)	Yes	FDA-approved
Wegovy with savings card	$25 (if eligible)	Yes, commercial only	FDA-approved
FormBlends compounded semaglutide	$179-$279	No	Not FDA-approved (compounded)
Other telehealth compounded semaglutide	$199-$499	No	Not FDA-approved (compounded)

Key differences:

• Compounded semaglutide is drawn from a vial with a syringe rather than delivered by a pre-filled pen
• It's not FDA-approved (compounded medications are regulated by state pharmacy boards, not FDA)
• It's typically sold through telehealth platforms with a monthly subscription model
• No prior authorization required
• No insurance paperwork

When compounded makes sense:

• Your insurance doesn't cover Wegovy
• You don't qualify for the savings card (Medicare, Medicaid, uninsured)
• Your copay is over $200/month
• You want predictable pricing without annual benefit caps
• You're comfortable with non-FDA-approved medication

When brand-name Wegovy makes sense:

• Your copay is under $100/month
• You qualify for the PAP and can get Wegovy free
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled pen

Clinical equivalence: Compounded semaglutide uses the same active pharmaceutical ingredient (semaglutide base) as Wegovy. The difference is the preparation method (compounded in a pharmacy vs manufactured in an FDA-inspected facility) and delivery device (vial and syringe vs pen).

No head-to-head trials compare compounded semaglutide to brand-name Wegovy. The STEP trials (Wilding et al., NEJM 2021; Wadden et al., JAMA 2021) tested brand-name semaglutide. Real-world effectiveness of compounded semaglutide is based on patient-reported outcomes and prescriber experience, not randomized controlled trials.

FormBlends compounded semaglutide starts at $179/month and includes provider consultations, medication, syringes, and alcohol swabs. No hidden fees, no insurance required.

Strategy 6: Canadian pharmacy imports (legal gray area)

Importing Wegovy from a Canadian pharmacy costs $450 to $650 per month, roughly half the U.S. cash price. This strategy exists in a legal gray area: technically illegal under FDA rules, but rarely enforced for personal-use quantities.

How it works:

1. You obtain a valid U.S. prescription for Wegovy
2. You submit the prescription to a licensed Canadian pharmacy (online or by mail)
3. The pharmacy ships a 3-month supply to your U.S. address
4. You pay $1,350 to $1,950 for three months ($450 to $650/month)

Legal status: The FDA prohibits importing prescription medications from foreign pharmacies. The exception is personal-use quantities (typically 90-day supply) for medications not available in the U.S. or available only at prohibitive cost. The FDA rarely enforces this rule for individual patients importing from Canadian pharmacies.

Several states (Florida, Colorado, Vermont) have passed laws explicitly allowing Canadian imports, and the FDA has authorized state-level importation programs (FDA 2020 guidance). Individual imports remain technically illegal but practically unenforced.

Risks:

• Shipments can be seized by customs (rare, under 2% based on Canadian pharmacy industry estimates)
• No recourse if medication is damaged in transit
• Longer supply-chain time (10 to 21 days shipping)
• Some Canadian pharmacies are fraudulent (sell counterfeit medication or never ship)

How to verify a legitimate Canadian pharmacy:

• Check CIPA certification (Canadian International Pharmacy Association)
• Verify the pharmacy is licensed in its province (search the provincial pharmacy regulator website)
• Confirm the pharmacy requires a valid prescription (if they sell without a prescription, they're not legitimate)
• Use PharmacyChecker.com to verify the pharmacy's credentials

Cost comparison: A 3-month supply of Wegovy from a CIPA-certified Canadian pharmacy costs approximately $1,650 to $1,950 ($550 to $650/month) including shipping. The same 3-month supply in the U.S. without insurance costs $4,047 ($1,349/month).

This strategy makes sense for patients who don't qualify for savings cards or PAP, prefer brand-name Wegovy over compounded semaglutide, and are comfortable with the legal gray area.

Strategy 7: Clinical trial enrollment

Active clinical trials testing semaglutide or next-generation GLP-1 medications provide free medication, free medical monitoring, and sometimes stipends for participation.

Current trials (as of April 2026): ClinicalTrials.gov lists 47 active trials recruiting participants for semaglutide or tirzepatide studies. Most are Phase 3 or Phase 4 trials testing new indications (cardiovascular outcomes, kidney disease, Alzheimer's prevention) rather than weight loss specifically.

Typical eligibility:

• BMI ≥27 or ≥30 (varies by trial)
• Age 18-75
• No current GLP-1 use (most trials require a washout period)
• Willing to attend in-person visits every 2-4 weeks
• No history of pancreatitis, medullary thyroid cancer, or MEN2

What you receive:

• Free study medication for the trial duration (typically 52 to 104 weeks)
• Free lab work, imaging, and medical monitoring
• Compensation for time and travel ($50 to $150 per visit is common)

Trade-offs:

• You might be randomized to placebo (most trials are 2:1 or 3:1 active:placebo)
• Frequent medical visits (every 2-4 weeks)
• Strict protocol adherence required
• Trial can be terminated early if safety concerns arise

How to find trials: Search ClinicalTrials.gov for "semaglutide" or "GLP-1 agonist" and filter by "recruiting" status and your location. Contact the trial coordinator listed on the study page.

Trial enrollment makes sense for patients who want free medication, are comfortable with the possibility of placebo, and have schedule flexibility for frequent visits.

The FormBlends Cost Decision Framework

We've built a decision framework based on pattern recognition across 3,400+ patient cost consultations between January 2024 and March 2026. This is not a clinical protocol but a practical navigation tool.

The framework has three decision nodes:

Node 1: Insurance status

• Commercial insurance → Attempt savings card first (Strategy 1)
• Medicare/Medicaid → Skip to compounded semaglutide (Strategy 5) or Canadian import (Strategy 6)
• Uninsured → Check PAP eligibility (Strategy 2), then compounded semaglutide (Strategy 5)

Node 2: Income level

• Income under 400% FPL → Apply for PAP (Strategy 2) regardless of insurance status
• Income over 400% FPL → Proceed to Node 3

Node 3: Monthly budget tolerance

• Can afford $200+/month → Use insurance with or without savings card
• Can afford $100-$200/month → Compounded semaglutide or plan switch during open enrollment
• Can afford under $100/month → PAP, clinical trial, or delay treatment until financial situation changes

The pattern we see most often: Patients attempt strategies in the wrong order and waste 60-90 days. The most efficient path is PAP application (if income-eligible) submitted the same day as the first prescription, with compounded semaglutide as the backup during the PAP approval window. This approach gets medication started within 7 days and transitions to free brand-name Wegovy once PAP approves.

The second-most-common pattern: Patients eligible for the savings card don't realize the 13-month cap exists and face a surprise $400+ copay in month 14. The solution is to set a calendar reminder in month 11 to begin the PAP application or transition to compounded semaglutide before the savings card benefit expires.

Diagram suggestion: Three-node flowchart with "Insurance status" at top branching to three paths, each path leading to "Income level" node, each income branch leading to "Budget tolerance" node, each budget node showing final recommended strategy.

When you should NOT pursue cheaper Wegovy

The strongest argument against cost-reduction strategies is that some strategies introduce clinical trade-offs that outweigh the financial benefit.

Scenario 1: You have well-controlled type 2 diabetes on brand-name Ozempic. Switching to compounded semaglutide to save money might destabilize your glucose control during the transition. The dosing precision of the Ozempic pen (0.25 mg, 0.5 mg, 1 mg, 2 mg fixed doses) is higher than drawing from a compounded vial. If your HbA1c is 6.2% and stable, the $100/month savings from switching to compounded may not justify the risk of losing glycemic control.

Scenario 2: You've achieved goal weight on Wegovy and are considering stopping to save money. The STEP 4 trial (Rubino et al., JAMA 2021) showed that patients who stopped semaglutide after 20 weeks regained two-thirds of lost weight within 48 weeks. If you've lost 60 pounds and stop Wegovy to avoid the cost, you'll likely regain 40 pounds. The cost of regaining weight (renewed obesity-related complications, need to restart medication, psychological impact) often exceeds the cost of continuing treatment.

Scenario 3: You're considering Canadian imports but have a history of medication non-adherence. If you've previously stopped medications because you ran out between refills, the 10-21 day shipping time for Canadian imports creates a gap risk. Missing even one week of semaglutide can trigger rebound hunger and weight regain. The $700/month savings from Canadian imports vs U.S. cash price is irrelevant if supply-chain delays cause you to discontinue treatment.

Scenario 4: You qualify for the PAP but your provider refuses to complete the paperwork. Some patients switch providers to find one willing to complete PAP applications. If your current provider has deep knowledge of your medical history and strong clinical rapport, switching providers to save money on Wegovy might compromise your overall care quality. The decision depends on whether you can find an equally qualified provider who will complete the paperwork.

The general principle: cost reduction makes sense when it doesn't compromise treatment adherence, clinical monitoring, or medication consistency. When the cheaper option introduces risks that could derail your treatment entirely, the higher-cost option is often the better choice.

How to verify your specific cost in 10 minutes

Step 1 (2 minutes): Check your insurance formulary. Log into your insurance member portal. Search the formulary for "Wegovy" or "semaglutide." Note the tier (Tier 2, 3, 4, or excluded) and whether prior authorization is required.

Step 2 (3 minutes): Call your pharmacy. Call the pharmacy you plan to use. Give them your insurance information and ask them to run a test claim for Wegovy 2.4 mg. They'll tell you your exact copay without filling the prescription.

Step 3 (2 minutes): Download the savings card. Go to wegovy.com/savings-and-coverage. Download the savings card. If you have commercial insurance, bring it to the pharmacy with your insurance card.

Step 4 (2 minutes): Check PAP eligibility. Calculate your household income as a percentage of federal poverty level using the calculator at coverageforall.org/fpl-calculator. If you're under 400%, download the PAP application.

Step 5 (1 minute): Compare against compounded semaglutide. Visit formblends.com and complete the 60-second eligibility quiz. You'll see your compounded semaglutide cost immediately.

At the end of 10 minutes, you'll have:

• Your exact insurance copay
• Your savings card eligibility
• Your PAP eligibility
• Your compounded semaglutide cost

This eliminates the "I thought it would cost X but it actually costs Y" surprise that derails 30% of new Wegovy starts based on GoodRx's 2025 patient survey.

FAQ

How much does Wegovy cost without insurance? Wegovy's list price is $1,349 per month without insurance. GoodRx coupons can reduce this to $1,200 to $1,300, but the savings are minimal. Compounded semaglutide costs $179 to $299/month and doesn't require insurance.

Does the Wegovy savings card work if I have no insurance? No. The savings card requires commercial insurance that covers Wegovy. If you're uninsured, you don't qualify. Your options are the patient assistance program (if income-eligible), compounded semaglutide, or Canadian pharmacy imports.

Can I use GoodRx for Wegovy? Yes, but the discount is small. GoodRx typically reduces Wegovy from $1,349 to $1,200-$1,300. The savings card (if you have commercial insurance) reduces cost to $25, which is far better than GoodRx.

Does Medicare cover Wegovy? Medicare Part D does not cover Wegovy for weight loss as of April 2026. Some Medicare Advantage plans offer supplemental coverage, but it's rare. Medicare patients' best options are compounded semaglutide or the PAP if income-eligible.

Does Medicaid cover Wegovy? Coverage varies by state. As of 2026, 14 states cover Wegovy for weight management with prior authorization. The remaining states exclude it. Check your state Medicaid formulary or ask your provider to submit a PA.

How long does the Wegovy savings card last? The savings card covers up to 13 fills (13 months of treatment). After that, the benefit expires and you pay your plan's full copay. The program previously allowed 24 fills but changed in late 2025.

Is compounded semaglutide the same as Wegovy? Compounded semaglutide contains the same active ingredient (semaglutide) but is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. It's not FDA-approved and is drawn from a vial rather than delivered by pen. Clinical effectiveness is expected to be similar, but no head-to-head trials exist.

Can I buy Wegovy from Canada legally? Technically no, but the FDA rarely enforces the rule for personal-use quantities. Thousands of Americans import Wegovy and other medications from Canadian pharmacies monthly. Use only CIPA-certified pharmacies to avoid counterfeit medication.

What income level qualifies for free Wegovy through the PAP? Household income below 400% of federal poverty level. For 2026, that's $60,240 for an individual, $81,760 for a couple, $124,800 for a family of four. The threshold adjusts annually.

How do I appeal a Wegovy prior authorization denial? Call your insurance company and request a formulary exception appeal form. Your provider completes the clinical justification section. Submit within 60 days. Appeals have a 62% success rate according to recent data (Stokes et al., JAMA Health Forum 2025).

Can I switch from Wegovy to compounded semaglutide mid-treatment? Yes. The transition is straightforward because the active ingredient is the same. Your provider will convert your Wegovy dose to the equivalent compounded dose. Most patients transition without any gap in treatment or change in effectiveness.

Does FormBlends accept insurance for compounded semaglutide? No. FormBlends compounded semaglutide is a cash-pay service priced at $179 to $279/month. We don't process insurance claims, which allows us to avoid prior authorization delays and formulary restrictions.

Sources

1. Benner JS et al. Formulary placement and out-of-pocket costs for GLP-1 receptor agonists in U.S. commercial and marketplace plans. Health Affairs. 2024.
2. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3 trial). JAMA. 2021.
4. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4 trial). JAMA. 2021.
5. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT trial). New England Journal of Medicine. 2023.
6. Stokes A et al. Prior authorization denials and appeals for GLP-1 receptor agonists in commercial insurance. JAMA Health Forum. 2025.
7. Centers for Medicare & Medicaid Services. Medicare enrollment dashboard. 2025.
8. Kaiser Family Foundation. Medicaid enrollment data. 2025.
9. U.S. Census Bureau. Health insurance coverage in the United States. 2025.
10. Novo Nordisk. Annual report: patient assistance program utilization. 2025.
11. GoodRx. Patient survey: prescription cost surprises and abandonment. 2025.
12. FDA. Guidance for industry: importation of prescription drugs. 2020.
13. Canadian International Pharmacy Association. Verification database. 2026.
14. ClinicalTrials.gov. Active trials for semaglutide and tirzepatide. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Medicare, Medicaid, and TRICARE are government program names. GoodRx, PharmacyChecker, and ClinicalTrials.gov are trademarks or service marks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.